ESTRO 2024 - Abstract Book

S2396

Clinical - Urology

ESTRO 2024

PSA (ng/mL)

7.5

4.3

Prostate volume (cc)

38.4

19.5

Gleason Score:

N

%

G3+3=6

9

18

G3+4=7

36

73

G4+3=7

4

8

Relevant at-risk medications: a

Anti-platelet agent

9

18

Anticoagulant

5

10

Rectal dosimetry:

median

IQR

D1cc (Gy)

30.2

4.1

D2cc (Gy)

27.5

3.8

V50% (cc)

7.9

5.1

PTV coverage:

V36.25Gy (%)

98.8

1.2

a Anti-platelet agents: aspirin, clopidogrel. Anticoagulants: DOACs, warfarin

Figure 1

Conclusion:

Early clinical use of the iodinated hydrogel spacer SpaceOAR Vue TM is encouraging for very low rates of acute rectal toxicity. Longer term follow-up will determine the incidence of late rectal toxicity. The role of SpaceOAR Vue TM in prostate stereotactic ablative radiation is currently being evaluated in the international multi-centre prospective phase 3 SABRE trial, NCT04905069. 1